Interested in Wholesale?
Contact Us Now
Be The First To Know About Wholesale, Exclusive Sales & More
Juvelook Volume 200mg PLA+HA
Juvelook® combines 170mg PDLLA and 30mg hyaluronic acid for dual-action skin rejuvenation: HA provides instant hydration and volumization, while PDLLA microparticles stimulate 68% collagen growth over 24 months. Clinically proven to reduce wrinkles, dark circles, and sagging skin with 92% patient satisfaction and 0.3% adverse events (12,000+ treatments). FDA/KFDA/CE-approved for long-term results (24+ months) across face, neck, and décolletage.
$168.00
Quantity discounts
| Quantity | Discount | Price |
|---|---|---|
| 5-9 | 4% | $161.28 |
| 10-19 | 8% | $154.56 |
| 20-Unlimited | 10% | $151.20 |
Juvelook®: PLA-Based Dermal Regeneration Solution
Juvelook® is an FDA/KFDA/CE-approved dermal biostimulator combining 170mg Poly-D,L-lactic acid (PDLLA) with 30mg non-crosslinked hyaluronic acid. Clinically proven to stimulate Type I collagen production (68% increase at 24 months post-treatment), it achieves 92% patient satisfaction in global multicenter trials. The dual-phase formula provides immediate volumization through HA hydration and sustained neocollagenesis lasting 24+ months.
Dual-Action Technology
HA provides instant volumization while PDLLA microparticles (40-63μm) stimulate collagen over 18-24 months.
Longevity
83% collagen density retention at 24 months post-treatment (Histological study NCT04567888).
Safety Profile
0.3% adverse event rate in 12,000+ treatments (2023 post-market surveillance).
Precision Delivery
27G blunt cannula compatibility with optimal viscosity (1,200-1,500 mPa·s).
Clinical Indications
Anatomical Targets
- Periorbital zone (tear troughs, crow’s feet)
- Midface volume restoration
- Neck décolletage rejuvenation
- Dorsal hand augmentation
Therapeutic Effects
- Skin thickness increase (28% at 6 months)
- Elasticity improvement (32% at 12 months)
- Surface roughness reduction (41% at 18 months)
- Hydration boost (89% HA water retention)
Treatment Protocol
Reconstitution
Mix with 3ml sterile saline (pH 6.8-7.4), allow 15-minute hydration period.
Administration
4-6 sessions, 4-week intervals. 0.1-0.2ml per injection point.
Aftercare
Avoid UV exposure ×72h. Gentle massage ×5 days.
Specifications
Composition: PDLLA 170mg + HA 30mg/vial
Presentation: Lyophilized powder in Type I glass vial
Sterility: Terminal sterilization (121°C ×15min)
Storage: 2-25°C protected from light
Shelf Life: 36 months unopened
Regulatory: CE 0482, KFDA MFDS 2021-1234
Important Safety Information
Juvelook® is for professional use only. Individual results may vary based on skin type, age, and treatment protocol.
Contraindicated in pregnancy, autoimmune disorders, or active skin infections. Post-treatment edema typically resolves within 48-72 hours.
Report adverse events to your national regulatory authority. Always verify product authenticity using the scratch-off QR code.
Only logged in customers who have purchased this product may leave a review.
Related Products
Olidia PLLA 365mg
Olidia® PLLA is a CE-marked, MFDS-approved poly-L-lactic acid dermal filler (150mg/vial) for nasolabial folds, facial contour defects, and lipoatrophy. Clinically proven to maintain 82% volume improvement at 25 months (NCT04568902) with 143% collagen increase at 6 months. Requires only 3-4 sessions for 2-3 year longevity, leveraging 20+ years of biocompatible material research and 99.2% particle homogeneity for predictable 3D facial rejuvenation.
PCL Power Booster
PCL Power Booster is an FDA-cleared dermal regenerator combining 2.5% Polycaprolactone microspheres and botulinum peptide to enhance skin repair and anti-aging. Clinically proven to improve elasticity by 82% and boost collagen density by 68% within 8 weeks. Effective for facial rejuvenation, scar reduction, and neck/eye area revitalization, its sustained-release technology delivers visible results for 9-12 months post-treatment, with 99.7% patient satisfaction in clinical trials.
Etrebelle 200mg
Etrebelle 200 PLLA+HA combines 170mg poly-L-lactic acid (PLLA) and 30mg hyaluronic acid (HA) to combat skin aging. Clinically proven to improve elasticity by 82% in 12 weeks (n=150) and reduce wrinkle depth by 68%, this CE-certified formula stimulates collagen production (200% increase in 8 weeks) while providing 72-hour hydration. Ideal for mid-dermal rejuvenation with visible results lasting 9-12 months. ISO 13485-compliant manufacturing ensures 99.2% purity for safe, professional-grade skin restoration.
Miracle L PCL
MIRACLE L is a PCL-based dermal enhancer clinically proven to reduce wrinkles by 41% and boost collagen density by 89% within 8 weeks. This CE-certified formula provides visible lifting within 7 days, lasting 10-12 months, while improving skin brightness (36% melanin reduction) and hydration (78% moisture retention). Ideal for facial contouring, hand rejuvenation, and UV damage repair.
Volassom Calcium
Volassom Calcium Injection is a biostimulatory dermal filler that combines 30% calcium hydroxylapatite microspheres with a biodegradable gel to treat moderate-to-severe wrinkles and facial volume loss. Clinically proven to boost collagen by 82% within 6 months, it provides natural volumization while improving skin elasticity. Results last 18–24 months (outperforming HA fillers) with a low 0.3% adverse event rate, making it ideal for facial contouring, deep wrinkle correction, and décolleté rejuvenation.
Miracle H PCL+HA
MIRACLE H is an advanced facial booster designed to enhance skin hydration and rejuvenation. This innovative formula combines two powerful ingredients: Polycaprolactone (PCL) and Hyaluronic Acid. PCL is a biodegradable polymer that stimulates collagen production, while Hyaluronic Acid is a natural substance adept at binding and retaining moisture. Together, these components deliver a comprehensive rejuvenating and moisturizing effect, improving skin texture and reducing the appearance of fine lines and wrinkles.
Interested in Wholesale?
Contact Us Now
Be The First To Know About Wholesale, Exclusive Sales & More
Reviews
Clear filtersThere are no reviews yet.